COVID-19: US Company, Novavax, Set to Commence Human Trials of 'Recombinant Vaccine' - THISDAYLIVE

  • 📰 THISDAY LIVE
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 51%

Business News News

Business Business Latest News,Business Business Headlines

COVID-19: US Company, Novavax, Set to Commence Human Trials of 'Recombinant Vaccine' via thisdaylive

An American biotechnology company, Novavax, is set to commence human trials of COVID-19 vaccine in Australia.

Novavax Research Chief, Dr Gregory Glenn, who spoke during a virtual press conference in Melbourne from Novavax’ headquarters in Maryland, US, said the firm had commenced the first phase of the trial in which 131 volunteers will be tested, adding that the volunteers will be from the cities of Melbourne and Brisbane and that the test will look for early signs of the vaccine’s effectiveness.

Many experimental vaccines are in early stages of testing or will begin testing across China, US, Europe. Vaccines are being created with different technologies, and work in different ways, which gives a possibility of at least one to succeed.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 14. in BUSİNESS

Business Business Latest News, Business Business Headlines